A gene editing technology developed at WSU is being licensed to Genus plc, a global animal genetics company, to develop cattle that are more resistant to bovine respiratory disease (BRD).
“From domestication and selective breeding to today’s use of advanced biotechnology, the goal of all animal husbandry remains the same,” said Bryan Slinker, dean of WSU’s College of Veterinary Medicine. “The goal is to continue to optimize animal health and well-being and produce disease-free food animals. This work is another important step in ensuring we meet our responsibilities to animals as well as the world’s food supply, now and in the future.”
A discovery by Washington State University scientist Dan Rodgers and collaborator Paul Gregorevic could save millions of people suffering from muscle wasting disease.
The result of the team’s four-year project is a novel gene therapeutic approach. The work was published (http://stm.sciencemag.org/content/8/348/348ra98) July 20 in Science Translational Medicine, a journal of the American Association for the Advancement of Science.
“It occurs with chronic infection, muscular dystrophy, malnutrition and old age,” he said. “About half the people who die from cancer are actually dying from muscle wasting and there’s not one single therapy out there that addresses it. » More …
Since the Commercialization Gap Fund launched at Washington State University two years ago, 14 researchers have received funding to fill the gap between their discoveries and private investment. The Washington Research Foundation (WRF) has just invested up to $1 million for the next four years in the fund.
“We have been impressed with the diversity of innovations at WSU,” said Beth Etscheid, director of research commercialization at the WRF (http://www.wrfseattle.org/), which established the fund with WSU in 2014. » More …
A new licensing partnership between WSU and Excellims Corp. will improve chemical detection tools used to detect everything from dangerous chemicals to human disease.
“I am very happy to see our research achievements being implemented into a commercial instrument,” said Herbert Hill, a WSU Regents Professor in the Department of Chemistry who developed the licensed technology. “This will allow researchers in a variety of academic research and industrial research fields to have a more powerful tool based on ion mobility spectrometry.”
Congratulations to our very own, Dr. Sita Pappu, Director of the Office of Commercialization, for being recognized as a Woman of Distinction by the Women’s History Month Committee and the President’s Commission on the Status of Women. This distinguished honor recognizes Dr. Pappu’s professional contributions and service activities that span all of WSU’s campuses, and research and extension centers.
Dr. Pappu is an accomplished scientist, a goal-oriented and results-driven manager, a highly successful administrator, compassionate leader, and mentor to all. In just thirteen years at WSU, she has assembled an impressive list … » More …
The OC is pleased to award 7 WSU researchers with a grant from the FY2015 Commercialization Gap Fund (CGF). The awards are intended to be the final funding step to advance innovations from the lab to the marketplace. In collaboration with the OC, CGF recipients will work to reach key milestones throughout the duration of the 12-month funding cycle.
The awardees include:
Dr. Amit Bandyopadhyay, Voiland College of Engineering and Architecture (Pullman) Project Title: Next Generation Infection Resistant Load-Bearing Implants
Dr. Clifford Berkman, College of Arts and Sciences (Pullman) Project Title: Tunable pH – Sensitive Linker for Targeted Drug Delivery
The Life Sciences Discovery Fund announced nearly $750,000 in Proof of Concept grants to Washington state for-profit and non-profit organizations, looking to promote translation of health related technologies from the lab to the marketplace. In addition, an existing grant was expanded by $56,000 to increase the commercial potential of a drug to protect hearing in patients taking certain antibiotics.
The awards will advance the development of products to improve lupus treatment, permit at-home monitoring of lung function for individuals with asthma, chronic obstructive pulmonary disease, and other conditions. In addition, the funding will also support validation of novel cell separations technology for cancer immunotherapy and … » More …